New drug XMT-1660 enters first human tests for Hard-to-Treat cancers

NCT ID NCT05377996

First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times

Summary

This early-phase study tests a new drug called XMT-1660 in about 319 people with advanced solid tumors, including breast, ovarian, and endometrial cancers. The main goals are to find the safest dose and check for side effects. Researchers will also see if the drug shrinks tumors. This is a first-in-human trial, so the main focus is safety.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADENOID CYSTIC CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Avera Cancer Institute

    RECRUITING

    Sioux Falls, South Dakota, 57105, United States

  • Beth Israel Deaconess Medical Center

    RECRUITING

    Boston, Massachusetts, 02215, United States

  • Comprehensive Cancer Centers of Nevada

    RECRUITING

    Las Vegas, Nevada, 89169, United States

  • Dana-Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215, United States

  • Florida Cancer Specialists

    RECRUITING

    Sarasota, Florida, 34232, United States

  • Fred Hutchinson Cancer Center

    RECRUITING

    Seattle, Washington, 09109, United States

  • Henry Ford Health Hospital

    RECRUITING

    Detroit, Michigan, 48202, United States

  • Huntsman Cancer Institute

    RECRUITING

    Salt Lake City, Utah, 84112, United States

  • ICHAN School of Medicine at Mount Sinai

    RECRUITING

    New York, New York, 10029, United States

  • MD Anderson

    RECRUITING

    Houston, Texas, 77030, United States

  • Mayo Clinic - Jacksonville

    RECRUITING

    Jacksonville, Florida, 32224, United States

  • Mayo Clinic - Rochester

    RECRUITING

    Rochester, Minnesota, 55905, United States

  • Mayo Clinic Comprehensive Cancer Center

    RECRUITING

    Phoenix, Arizona, 85054, United States

  • Memorial Sloan Kettering Cancer Center

    RECRUITING

    New York, New York, 10065, United States

  • Moffitt Cancer Center

    RECRUITING

    Tampa, Florida, 33612, United States

  • NEXT Oncology Virginia

    RECRUITING

    Fairfax, Virginia, 22031, United States

  • New York University Langone Health

    RECRUITING

    New York, New York, 10016, United States

  • Northwestern University

    RECRUITING

    Chicago, Illinois, 60611, United States

  • Sarah Cannon Research Institute (SCRI)

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • Stephenson Cancer Center Oklahoma University Health

    RECRUITING

    Oklahoma City, Oklahoma, 73104, United States

  • Summit Cancer Centers

    RECRUITING

    Spokane, Washington, 99208, United States

  • Texas Oncology, P.A.

    RECRUITING

    Dallas, Texas, 75251, United States

  • UC Irvine Health-Chao Family Comprehensive Cancer Center

    RECRUITING

    Orange, California, 92868, United States

  • UCLA David Geffen School of Medicine, Division of Hematology/Oncology

    RECRUITING

    Santa Monica, California, 90404, United States

  • UCSF Helen Diller Family Comprehensive Cancer Center

    RECRUITING

    San Francisco, California, 94158, United States

  • Winship Cancer Institute, Emory University

    RECRUITING

    Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.